The retail sector delivered a mixed performance during the festive season, with select pockets emerging as bright spots, ...

Dr. Reddy’s Laboratories shares rose 4% after Nuvama upgraded its rating to 'buy,' citing proactive strategies to mitigate ...

Nuvama assigned a target price of Rs 1,553 per share on Dr. Reddy's stock, implying an upside of 14.8% from the previous ...

Dr Reddy’s share price rose nearly 4% after Nuvama Institutional Equities upgraded its rating to ’Buy’ with a target of ...

Zypp Electric is in advanced talks to raise $25-30 million from investors led by Nuvama Wealth. Tribe Capital is ...

The surge in Dr. Reddy's share followed an upgrade by domestic brokerage Nuvama, which raised its rating on the stock to 'Buy ...

Semaglutide and Abatacept to offset revenue losses and 80% of EBITDA impact from the Revlimid patent expiry in 2026.

TARIL is undertaking an ambitious capacity expansion program, which will not only make the company India’s largest ...

The capital market regulator, in its January 2 order, barred both Parekh and Singapore-based Rohit Salgaocar, who was a ...

Find all the latest updates related to the FY25 Q3 results of TCS, Tata Elxsi, IREDA, Padam Cotton Yarns, GTPL, Vivo Bio Tech ...

Nomura, on January 6, upgraded SBI Card share to ‘Buy’ from ‘Reduce’ on rising share of top metro cities in its new card ...